Pharminent

AstraZeneca ups investment in messenger RNA drugs with Ethris deal

FRANKFURT (Reuters) – AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.

https://www.reuters.com/article/us-astrazeneca-ethris-idUSKCN1B10ZR

Filed under: Company